Elixinol Global Ltd (ELLXF)

[ShtockMahket]

Those potentially could be tailwinds, but in the US this is a very crowded space and Elixinol may struggle to maintain or grow their market share specifically in the US due to the sheer amount of competition they face here and their international strategy. I will say as well that I'm not too optimistic on FDA actions regarding CBD given their current stance. It's dangerous to speculate on this stuff, and one of the main reasons I'm long on Elixinol is because their focus on growth in Europe and elsewhere outside of the US should provide somewhat greater stability than companies focused solely on NA markets. Sector-wide, I just don't see the same optimism as before and I doubt Elixinol can stage a sustained move higher in the near-term as a result. Look at the price action since the Q1 disappointment... very choppy, but also very downbeat--just like most others in the sector.